Introduction
After an acute radiation disaster caused by either a nuclear power plant accident, a possible terrorist attack, or nuclear warfare, the first responders and civilians are at high risk of exposure to lethal doses of ionizing radiation (IR). The hematopoietic system is highly sensitive to IR, and in particular, IR doses beyond 2 Gy can lead to myelosuppression that is characterized by neutropenia, lymphocytopenia, and thrombocytopenia. Collectively, hematopoietic acute radiation syndrome (H-ARS) increases the risk of infection, bleeding, and death (1) (2) (3) (4) (5) (6) (7) (8) (9) . There is an unmet need for effective interventions to mitigate the progression of H-ARS after IR exposure (10) .
Maintenance of hematopoietic homeostasis and reconstitution after myeloablation relies solely on the self-renewal capability of hematopoietic stem progenitor cells (HSPCs). HSPC self-renewal is regulated by both intrinsic and extrinsic signals that are governed by BM stromal cells, such as osteoblasts and ECs (11) . Inhibition of HSPC self-renewal or myelosuppression induced by IR is a direct consequence of DNA damage, leading to apoptosis, senescence, or cell cycle arrest (2, 12, 13) . Antioxidants, antiapoptotic cytokines, or hematopoietic growth factors that could improve HSPC survival, maintenance, and/ or proliferation are being evaluated as radiomitigators (14) (15) (16) .
Nuclear factor erythroid-2-related factor 2 (NRF2) regulates an adaptive cytoprotective response to counteract the deleterious effects of ROS, such as DNA damage and apoptosis, and confers cytoprotection following exposure to environmental oxidants (17) (18) (19) (20) (21) (22) . Upon activation, NRF2 dissociates from its cytosolic inhibitor KEAP1 and mediates transcriptional activation of its target genes, which include multiple antioxidants and electrophile detoxification enzymes (17, 19, 23) . The radioprotective role of NRF2 is evident in a wide variety of cells and is mediated by increasing DNA repair responses (20) , neutralizing ROS, and reducing apoptosis (21) . Recently, we and others (24) have shown that HSPCs isolated from NRF2-deficient (Nrf2 -/-) mice failed to reconstitute following bone marrow transplantation (BMT). Here, we report that oral administration of a pharmacological NRF2 activator improves HSPC function and mitigates myelosuppression and mortality in mice, even 24 hours after total body irradiation (TBI). Importantly, we show for what we believe to be the first time that NRF2 enhances the repopulating capacity of HSPCs in BM by activating Notch signaling via intrinsic and extrinsic mechanisms. Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI70812DS1). Analysis of hematopoietic cells from BM, defined as LIN -SCA1 + c-KIT + cells (LSK cells; highly enriched for long-term and short-term HSCs and multipotent progenitor [MPP] cells; herein referred to as HSPCs) (24) , revealed that expression of Keap1 was reduced, while expression of NRF2-regulated antioxidant genes Nqo1 and Gclm was significantly elevated in MxCre-Keap1 -/mice compared with that in floxed controls, demonstrating activation of NRF2 in HSPCs ( Figure 1A ). Although the antioxidants were elevated, the constitutive levels of ROS in LSK cells from MxCre-Keap1 -/and Keap1 flox/flox mice were comparable (Supplemental Figure 2 ). Examination of peripheral blood (PB) 4 weeks after poly(I:C) treatment revealed no significant increase in total leukocyte counts, but the number of platelets was significantly higher in MxCre-Keap1 -/mice compared with that in poly(I:C)treated floxed controls (Supplemental Table 1 ) under steadystate conditions. Next, we assessed whether augmenting NRF2 in hematopoietic cells affects hematopoiesis in steady-state conditions. MxCre-Keap1 -/mice showed a higher percentage of LSK cells among the total BM cells, which resulted in a 1.7-fold increase in the absolute number of LSK cells compared with that in Keap1 flox/flox mice (Figure 1 , B-D). Flow cytometric analysis of LSK cells revealed no significant changes in the frequency of HSCs (CD150 + CD48 -), but a statistically significant increase in the frequency of MPP cells (CD48 -CD150 -) in MxCre-Keap1 -/mice compared with Keap1 flox/flox mice ( Figure 1E ), resulting in 2.5 and 2.3-fold increases in the absolute number of HSCs and MPP cells, respectively (Figure 1F) . Of note, we did not observe any significant difference in the population of BM stromal cells (identified as CD45 -TER119 -) between MxCre-Keap1 -/and Keap1 flox/flox mice in steady-state conditions (Supplemental Figure 3 , A and B). Next, we assessed the in vitro colony-forming activity of LSK cells to determine whether augmenting NRF2 alters the frequency of committed progenitor cells. We observed a statistically significant increase in total CFU, which was contributed mainly by GM-CFU and CFU granulocytes (G-CFU) in MxCre-Keap1 -/mice compared with that found in Keap1 flox/flox mice, indicating enhanced functional properties of MxCre-Keap1 -/-HSPCs ( Figure 1G ). However, under steady-state conditions in vivo, the number of myeloid progenitors (such as granulocyte-monocyte progenitors [GMPs], common lymphoid progenitors [CLPs] , and megakaryocyte erythroid progenitors [MEPs] ) was comparable between MxCre-Keap1 -/and Keap1 flox/flox mice (Supplemental Figure 3 , C and D).
Results

Activation of NRF by genetic disruption of
To assess HSPC function in vivo, we performed competitive transplantation of LSK cells isolated from MxCre-Keap1 flox/flox or Keap1 flox/flox mice 4 weeks after poly(I:C) injection into lethally irradiated WT mice (CD45.1). Eight and 14 weeks after BMT, PB analysis of recipient mice showed greater engraftment of donor cells derived from poly(I:C)-injected MxCre-Keap1 flox/flox mice compared that seen in Keap1 flox/flox mice (Figure 2 , A-C), indicating that gain of NRF2 function in HSPCs improves their short-term repopulating capacity. To further clarify the intrinsic role of NRF2 in HSPCs, we injected primary recipient WT mice (CD45.1) with poly(I:C) after competitive transplantation with LSK cells isolated from MxCre-Keap1 flox/flox or Keap1 flox/flox mice and analyzed donor cell chimerism. Three weeks after BMT, poly(I:C)-treated recipient mice transplanted with MxCre-Keap1 flox/flox donor cells showed a higher total number of CD45.2 cells compared with that in poly(I:C)-injected recipient mice transplanted with Keap1 flox/flox donor cells ( Figure 2 , D and E). Poly(I:C) injection induces type 1 IFN signaling and activates HSC proliferation (25) . To exclude any effect of poly(I:C) on our results, we transplanted BM cells from primary transplant recipients into a secondary group of lethally irradiated WT mice. PB analysis showed a higher number of total donor CD45.2 cells and multilineage engraftment, with significantly higher numbers of myeloid lineage (GR1 + ) cells in the secondary recipient mice (CD45.1) that received BM from poly(I:C)-injected primary recipient mice transplanted with MxCre-Keap1 flox/flox LSK cells compared with those found in Keap1 flox/flox mice (Figure 2 , D-F, and Supplemental Figure 4 ).
HSPCs reside in a specialized microenvironment located in the BM, referred as the "niche," and it has been well demonstrated that BM stromal cells tightly regulate HSPC maintenance and expansion through extrinsic signals (26, 27) . To gain insight into a possible role of NRF2 in BM stromal cells in the regulation of HSPC function, we used tamoxifen-inducible CMVCre-Keap1 flox/flox mice, in which tamoxifen treatment induced whole-body Keap1 deletion (Supplemental Figure 5A ). Tamoxifen-treated CMVCre-Keap1 flox/flox mice showed reduced expression of the Keap1 gene and increased expression of NRF2-regulated genes in whole BM and CD45 stromal cells (Supplemental Figure 5B and Figure 2H ) compared with tamoxifen-treated Keap1 flox/flox mice. Similar to the MxCre model, we observed a significant increase in the frequency of the LSKcell population in tamoxifen-treated CMVCre-Keap1 flox/flox mice compared with that seen in Keap1 flox/flox mice (Supplemental Figure 5C ). To address the role of Keap1 -/-BM stromal cells in enhancing HSPC function, we cultured WT LSK cells with BM stromal cells isolated from tamoxifen-treated CMVCre-Keap1 flox/flox or Keap1 flox/flox mice and analyzed the expansion of LSK cells. After 7 days of coculture, the expansion of LSK cells was approximately 50% higher in CMVCre-Keap1 -/stromal cells than in Keap1 flox/flox stromal cells (Figure 2 , G-I, and Supplemental Figure 5D ). These results suggest that augmenting NRF2 signaling in BM stromal could promote HSPC expansion via extrinsic signals.
Pharmacological activation of NRF2 enhances hematopoietic reconstitution following BMT. We next evaluated whether pharmacological activation of NRF2 augments the repopu-lating capacity of HSPCs. We have previously shown that 2-trifluoromethyl-2′-methoxychalcone (TMC), a synthetic chalcone derivative, is a potent small-molecule NRF2 activator (28) . Multiple oral administrations of TMC (6 times, once every 48 hours) upregulated NRF2-dependent target genes Nqo1, Gclm, and Ho1 in BM cells and other tissues (such as small intestine) of mice (Supplemental Table 2 ). A CFC assay showed that administration of TMC (6 times, once every 48 hours) significantly elevated functional hematopoietic progenitor cells in the BM; however, the total number of LSK cells was unaffected compared with that in vehicle-treated mice under steady-state conditions (Supplemental Figure 6 , A and B). We also noted that daily oral administration of TMC for 2 weeks in healthy mice did not affect the PB counts and caused no apparent renal or hepatic toxicity (Supplemental Table 3 ). To determine whether TMC administration promoted HSPC function in vivo, we transplanted WT BM cells (CD45.2) into lethally irradiated WT mice (CD45.1) and treated the recipient mice orally with TMC or vehicle 6 times following BMT (initiated 1 hour after BMT, and then once every 48 hours). Two weeks after BMT, the donor cell engraftment was approximately 50% and approximately 400% higher in PB ( Figure 2J ) and BM (LINcells; Figure 2K ), respectively, in recipient mice treated with TMC compared with those treated with vehicle. Taken together, these data suggest that pharmacological activation of NRF2 improves BMT.
Nrf2-null mice are more sensitive to TBI-induced mortality and myelosupression. The ability of NRF2 to increase hematopoietic reconstitution led us to hypothesize that pharmacological activation of NRF2 mitigates TBI-induced myelosuppression. To test this hypothesis, we used Nrf2 -/mice to determine whether NRF2 is a critical host factor for survival after TBI. In response to increasing doses of TBI, Nrf2 -/mice exhibited greater mortality ( Figure 3 , A and B) compared with Nrf2 +/+ mice. CFC assays showed greater reductions in functional hematopoietic progenitor cells in Nrf2 -/mice than in Nrf2 +/+ mice 48 hours after TBI (Supplemental Figure 7 ). Furthermore, on day 23 after TBI, Nrf2 -/mice had a lower blood cell count ( Figure 3C ) and BM LSK cell population ( Figure 3D ) than Nrf2 +/+ mice. Collectively, these results suggest that NRF2 is essential for protection against IR-induced myelosupression and mortality.
TMC treatment mitigates TBI-induced mortality and myelosupression in an NRF2-dependent manner. Next, we addressed whether augmenting NRF2 signaling with a pharmacological activator mitigates TBI-induced mortality. First, we sought to determine the baseline NRF2 activity in HSCs and BM stromal cells in mice after IR and whether TMC administration increases NRF2 activity in these BM compartments. NRF2 activity, as indicated by Nqo1 and Gclm expression, was markedly reduced in CD45 + LIN − (enriched for HSPC populations) and CD34 -LSK cells on days 1 and 2 and recovered to normal levels by day 12 following TBI. Similarly, NRF2 activity in BM stromal cells (CD45 -TER119 -) was significantly reduced on days 1 and 2, but was markedly increased by day 12 after TBI. However, oral administration of TMC every other day for a total of 6 doses, beginning 24 hours after TBI, significantly increased NRF2 activity in HSPCs and BM stromal cells compared with that observed in the vehicle-treated group (Figure 4 , A-C). Of note, we did not observe any change in expression of the Nrf2 gene following radiation exposure (Figure 4 , A-C), suggesting that the regulation of NRF2 activity is posttranscriptionally mediated (enhanced protein stability), as reported previously (19, (29) (30) (31) (32) (33) .
To test whether pharmacological activation of NRF2 mitigates radiation-induced mortality, mice were exposed to a range of TBI doses (6.9 Gy [LD 30/30 ], 7.1 Gy [LD 70/30 ], and 7.3 Gy [LD 100/30 ]) and were administered TMC or vehicle orally every other day for a total of 6 doses, beginning 24 hours after TBI. Then, we monitored the survival rate. Relative to vehicle, TMC administration dramatically improved the 30-day survival rate following 6.9 Gy (30% vehicle vs. 90% TMC; Figure 4D ) and 7.1 Gy (0%, vehicle vs. 70%, TMC; Figure 4E ) TBI doses. At a 7.3-Gy TBI dose, TMC administration failed to improve survival when administered 24 hours after IR; however, TMC significantly improved survival rates to 60% and 50% when started 1 hour and 6 hours after TBI, respectively ( Figure 4F ). We found that TMC administration 48 hours after a 6.9-Gy TBI dose failed to improve survival (Supplemental Figure 8 ). Furthermore, we observed that TMC administration failed to improve survival rates in Nrf2 -/mice following 6.9 Gy TBI, indicating that its specific mechanism of action is dependent on NRF2 activation ( Figure 4G ).
We validated the radiomitigative efficacy of TMC in the CD1 mouse strain. TMC administration 24 hours after TBI significantly increased survival of CD1 mice compared with vehicle-treated mice (Supplemental Figure 9 ). To verify that the radiomitigative potency of targeting the NRF2 pathway is not specific to TMC, we used another pharmacological activator of NRF2, CDDO-methyl ester (CDDO-Me, 2-cyano-3,12-dioxooleane-1,9(11)-dien-28-oic acid methyl ester) (34) (35) (36) . CDDO-Me is a synthetic triterpenoid that was under phase III clinical development for the treatment of advanced chronic kidney disease (37, 38) However, due to adverse events in the phase III clinical trial, further development of CDDO-Me was terminated (39) . Like TMC, we found that oral administration of CDDO-Me 24 hours after TBI (LD 30 or LD 100 dose) significantly increased NRF2 target gene expression (Supplemental Table 4 ) and improved the survival of C57BL/6 mice (Supplemental Figure 10 , A and B) in an NRF2-dependent manner (Supplemental Figure 10C ).
Next, we investigated whether TMC affected hematopoietic recovery in mice exposed to 6.9 Gy TBI. The decline in PB counts was similar in TMC-and vehicle-administered mice until day 12 after TBI ( Figure 5A ). However, TMC enhanced recovery of all PB cell lineages (neutrophils, monocytes, lymphoid cells, erythrocytes, and platelets) compared with those in vehicle-treated mice ( Figure 5 , A-C) from days 15 to 23 after radiation. Of note, oral administration of CDDO-Me 24 hours after TBI also showed enhanced recovery of all PB cell lineages after TBI (Supplemental Figure 11 ).
Concurrently, histological analysis of femurs on day 23 showed markedly higher BM cellularity in TMC-administered mice, compared with vehicle-treated mice ( Figure 5D and Supplemental Figure 12 ). Consistent with the higher neutrophil blood count, blood bacteremia, as assessed by blood cultures, was significantly reduced in TMC-administered mice compared with that in vehicle-treated mice ( Figure 5E ). These results confirm that TMC treatment mitigated TBI-induced mortality and myelosuppression in mice.
TMC treatment enhanced HSPC regeneration in irradiated mice. We analyzed the HSPC population in the BM of TMC-and vehicle-administered, irradiated mice. The number of HSC (LSK + CD48 -CD150 + ) and MPP cells (LSK + CD48 -CD150 -) decreased markedly by day 3 after TBI. However, TMC-treated mice showed a marked increase in the recovery of LSK, HSC, and MPP cell populations compared with that observed in vehicle-treated mice ( Figure 6A ) on day 21 after IR. This increase in HSPCs by day 21 corresponded with an approximate 3-fold increase in KI67 + cells, which are markers of proliferation, in the TMC-treated group compared with that observed in the vehicle-treated group ( Figure 6B ). To determine whether TMC treatment mediated radioprotection of HSPCs, we measured ROS levels, glutathione levels, and live and dead cells on day 3 after TBI. Although, TMC increased glutathione and reduced ROS in LSK cells ( Figure 6C ), the percentage of viable LSK cells on day 3 following TBI was elevated only modestly compared with that in vehicle-treated mice (Supplemental Figure 13A ). Also, there was no significant difference in the number of dead (Supplemental Figure 13B ) or apoptotic LSK cells between vehicle-and TMCtreated mice on day 3 after TBI (data not shown). These results suggest that TMC-mediated hematopoietic reconstitution in the irradiated mice was not mainly due to protection from radiation-induced cytotoxicity, but rather was a result of an augmented proliferation of the HSPC population. To further elucidate how TMC administration increased functional HSPC populations in irradiated mice, we performed a competitive repopulation assay (as shown in Figure 6D ). At 6 weeks, the recipient mice transplanted with BM cells from TMC-administered irradiated mice showed a 4-fold increase in the total number of CD45.2 cells and a significantly higher number of granulocytes (GR1 + ), B cells (B220 + ), and T cells (THY1.1 + ) in PB compared with those found in vehicle-treated controls (Figure 6 , E-G).
Augmenting NRF2 enhances HSPC expansion by upregulating Notch signaling. We next addressed how augmenting NRF2 signaling increases HSPC expansion in irradiated mice. By integrating global ChIP sequencing (ChIP-Seq) and transcriptomic profiles from cell models containing gain and loss of NRF2 function, we recently identified Jagged 1 (JAG1), a ligand for Notch1, as a direct transcriptional target of NRF2 (40) (41) (42) in embryonic fibroblast cells. Previous studies have shown that activation of Notch signaling enhances HSC self-renewal, while its loss impairs the maintenance of HSCs (43) (44) (45) (46) (47) (48) . Hence, we hypothesized that augmenting NRF2 could enhance HSPC expansion by activating Notch signaling. To address this, we first measured the expression of Notch1 and Notch target genes in BM cells after activating NRF2 signaling. BM cells from MxCre-Keap1 -/mice showed greater expression of Notch1 and the Notch target gene Hes1 compared with that seen in floxed controls ( Figure 7A ). Following TBI, TMC-treated mice showed greater expression of Notch1 and Hes1 in BM cells compared with vehicle-treated mice ( Figure 7B ). In addition, compared with vehicle, TMC administration markedly upregulated Jag1 (Figure 7C ure 14, A and B), in BM cells, and this upregulation peaked on day 7 following TBI. Next, to confirm that NRF2 activates Notch signaling in HSPCs, we used transgenic Notch reporter (TNR) mice, in which GFP is induced by Notch activation (49) . We found that TMC administration to unirradiated TNR mice significantly increased the percentage of GFP-positive LSK cells and colonyforming activity, but did not alter the total number of LSK cells in the BM as compared with that in vehicle-treated mice (Supplemental Figure 15 , A-C). In contrast, TMC administration to TNR mice following TBI increased the expression of GFP in bone sections and the frequency of GFP-positive LSK cells compared with vehicle-treated mice (Figure 7 , D and E), indicating an upregulation of Notch signaling. Finally, to determine whether Notch signaling is involved in mediating hematopoietic reconstitution following TMC administration, we cotreated vehicle-or TMC-administered irradiated mice with or without the Notch inhibitor γ secretase inhibitor II (GSI) (44). On day 12, we found that the population of LSK cells was significantly higher in TMC-treated irradiated mice compared with that in vehicle-treated mice ( Figure 7F ). However, GSI cotreatment abrogated the ability of TMC to repopulate the LSK cells in irradiated mice. Collectively, these findings confirm that TMC mediates hematopoietic reconstitution by activating the Notch signaling pathway. (50, 51) . We found that in vitro TMC treatment increased Nqo1, Gclm, and Jag1 mRNA expression in BM stromal cells isolated from unirradiated ( Figure 8, A and B ) and irradiated (data not shown) Nrf2 +/+ mice, but not in those from Nrf2 -/mice. To show that this elevated JAG1 expression is partly responsible for the NRF2-mediated increase in HSPC repopulation, BM stromal cells from irradiated Nrf2 +/+ or Nrf2 -/mice were exposed to TMC or vehicle ex vivo for 12 hours and subsequently cocultured with irradiated LSK cells. The expansion of LSK cells was markedly (2-fold) elevated in TMC-treated Nrf2 +/+ BM stromal cells compared with the vehicle-treated cells ( Figure 8C ), while blocking JAG1 binding to the Notch receptor by the anti-JAG1 antibody inhibited LSK cell expansion. In contrast, TMC-treated Nrf2 -/-BM stromal cells did not induce HSPC expansion compared with vehicle-treated cells ( Figure 8D ). Taken together, these results suggest that activation of NRF2 by TMC increases Notch signaling, partly by upregulating JAG1, and enhances HSPC repopulation through cooperation with BM stromal cells.
TMC enhances HSPC expansion by upregulating Jag1 in BM stromal cells in vitro. JAG1 expressed by the BM stromal cells interacts with the Notch receptor and induces survival and expansion of HSPCs in vitro and in vivo
Discussion
Regulators of ROS, cell cycle, and apoptosis play important roles in HSC self-renewal and maintenance under homeostatic condi-tions and in responses to genotoxic stressors such as radiation (2, 14, 43, 52, 53) . NRF2 regulates diverse cellular processes, which include redox regulation, apoptosis, and proliferation, by inducing a broad spectrum of cytoprotective proteins (19, 54) . Previously, using NRF2-null mice, we reported that NRF2 is essential for regulating HSPC function and hematopoiesis (24) . More recently, Tsai et al. (55) also confirmed that loss of NRF2 impairs the repopulating capacity of HSPCs following BMT. Defective in vivo function of Nrf2 -/-HSPCs was linked to HSPC exhaustion as a result of poor antioxidant defenses, diminished survival signaling (24) , and enhanced proliferation under steady-state conditions (55) . Here, we demonstrate for what we believe to be the first time that aug-
Figure 5
Administration of NRF2 activator TMC mitigates TBI-induced myelosuppression in mice. Mice exposed to 6.9 Gy TBI were administered 6 doses of vehicle or TMC (once every 48 hours), beginning 24 hours after TBI. At each time period indicated, a cohort of mice (n = 5-8) were sacrificed and PB was isolated. (A and B 
menting NRF2 activity by genetic disruption of KEAP1 in hematopoietic stem cells and/or BM stromal cells supports the repopulating capacity of HSPCs via intrinsic and extrinsic mechanisms.
Timely stimulation of HSPC proliferation is critical to early hematopoietic recovery and survival following TBI (56, 57) . Consistent with a previous study by McDonald et al. (58) , we found that lethal IR exposure caused greater mortality and hematopoietic toxicity in Nrf2 -/mice than in Nrf2 +/+ mice, indicating the protective role of NRF2 in radiation-induced myelosuppression. NRF2-deficient cells are shown to be sensitive to radiation-induced DNA damage, ROS, and cell death (58, 59) . Contrary to our expectations, we observed a marked downregulation of NRF2 activity in HSPCs until day 2 that was restored to baseline levels by day 12 in Nrf2 +/+ mice after TBI. In contrast, we found that BM stromal cells showed a similar decline in NRF2 activity until day 2 and then dramatic induction by day 12 after TBI. The mecha-nism for the delay in the activation of NRF2 in hematopoietic cells after TBI is unclear. Previously, McDonald et al. (58) also reported a marked delay in activation of NRF2 in cells exposed to IR, and it coincided with the rise in ROS generation. In a radiological emergency scenario, it is a realistic assumption that a medical countermeasure (MCM) will likely not be administered for a minimum of 24 hours after an acute radiation disaster (10). This 24-hour treatment window adds a stringent requirement for an effective MCM to mitigate the lethal effects of myelosuppression. Here, we demonstrated that TMC, when administered 24 hours after TBI, markedly improved survival of WT mice, but not Nrf2 -/mice, suggesting that the therapeutic efficacy of TMC is mediated selectively by activating the NRF2 pathway. We observed that TMC treatment in irradiated mice increased NRF2-regulated antioxidants in BM cells and other radiationsensitive tissues such as small intestine. This increase in anti-
Figure 6
Administration of NRF2 activator TMC enhances expansion of HSPCs in TBI-exposed mice. oxidant defenses in multiple organs may have contributed to improvement in the survival of TMC-treated mice after TBI. Nevertheless, TMC treatment 24 hours after TBI markedly enhanced hematological recovery and reduced blood bacteremia compared with vehicle-treated mice. Temporal PB and BM analysis showed that TMC treatment did not protect from early loss of circulating blood or HSCs; rather, it enhanced BM regeneration following TBI. In agreement with this, the percentage of live LSK cells was modestly elevated after treatment with TMC compared with vehicle treatment on day 3, even though TMC treatment elevated antioxidants and reduced ROS levels in LSK cells after TBI. In contrast, we found that the total number of LSK cells was markedly elevated by day 14 after TBI. In further support, we found greater engraftment of donor BM cells isolated from TMCtreated irradiated mice than was observed in vehicle-treated mice in a competitive transplantation experiment.
Notch signaling regulates cell fate decisions by controlling self-renewal and inducing differentiation (49, 60) . Recent findings suggest a complex role of Notch signaling in HSPC expansion and maintenance. In knockout mouse models of Notch1 or Notch2, canonical Notch signaling has been shown to be dispensable for HSC maintenance (61) . Conversely, activation of Notch signaling was shown to promote HSPC proliferation (62, 63) . Ectopic expression of Notch1 or ex vivo stimulation with the Notch ligand JAG1 enhanced cytokine-stimulated proliferation and survival of HSCs ex vivo and in vivo (62, 63) . In our study, we found that TMC treatment induced an approximately 3-fold increase in LSK cell proliferation in irradiated mice compared with that in vehicle-treated mice. Previously, we reported that NRF2 regulates transcriptional expression of Notch1 (41) . Activation of NRF2 promoted liver regeneration by activating Notch signaling (41) . We elucidated that TMC improved hematopoietic regeneration by upregulating Notch signaling in irradiated mice through activation of NRF2. In the present study, we found that compared with the respective control mice, LSK cells isolated from MxCre-Keap1 -/or TMC-treated irradiated mice showed elevated expression of Notch1 and Hes1. TMC treatment induced a 2-fold increase in Notch-activated LSK cells (GFP + cells) in irradiated TNR mice compared with that observed in vehicle-treated mice. Conversely, we found that the Notch inhibitor GSI abrogated TMC-induced improvement in hematopoietic regeneration in irradiated mice, suggesting that TMC improved hematopoietic regeneration by activating the Notch signaling cascade. JAG1 expressed by BM stromal cells interacts with Notch-expressing hematopoietic cells and stimulates expansion and survival of HSCs (64) . Recently, by global ChIP-Seq analysis, we reported that NRF2 regulates JAG1 expression in mouse embryonic fibroblast cells (42) ; however, the biological role of NRF2 in regulating HSPC function through JAG1 was not elucidated. In the present study, we found that in vivo TMC treatment markedly induced the expression of JAG1, but not of other Notch ligands, in BM stromal cells of irradiated mice). We observed that TMC exposure in in vitro cultures of BM stromal cells isolated from sham or irradiated Nrf2 +/+ mice, but not Nrf2 -/mice, increased the induction of JAG1 expression compared with that in vehicle-treated mice and supported an enhanced ex vivo expansion of LSK cells from irradiated mice in coculture conditions. Therefore, HSPC expansion in the BM of TMC-treated irradiated mice was partly driven by NRF2-regulated JAG1/Notch1 signaling.
In conclusion, we demonstrate here a previously unknown function of NRF2 signaling in the promotion of hematopoietic reconstitution after radiation-induced myeloablation and BMT. Furthermore, we elucidate a novel mechanism in which NRF2 regulates the repopulating capacity of HSCs by activating Notch signaling via transcriptional expression of Notch1 and Jag1. Our findings suggest a translational potential of the NRF2 activator TMC for improving hematopoietic cell transplantation and mitigating radiation-induced myelosupression in a nuclear accident scenario. medium (IMDM) with 2% FBS. Before staining, BM rbc were lysed using ACK Lysing Buffer (Quality Biological Inc.). For detection of LSK cells, whole BM cells were incubated with biotin-conjugated monoclonal antibodies against lineage markers (Miltenyi Biotec) including CD5, CD11b, CD45R, anti-7-4, anti-GR1, and anti-TER119. PE-SCA1 and APC-c-Kit (eBioscience) were costained with lineage markers. For detection of LT HSCs and MPP cells, PE-Cy7-CD150 (eBioscience) and Pacific Blue CD48 (BioLegend) antibodies were stained in addition to LSK markers. Note that to detect biotin-conjugated lineage markers, streptavidin-conjugated APC-Cy7 (eBioscience) was used. Stained cells were analyzed using an LSR II flow cytometer (BD Biosciences). For sorting of CD34-LSK cells, FITC-CD34 (eBioscience) antibody was used in addition to c-Kit, SCA1, and lineage markers. To sort live cells, 7-AAD was used and sorted by a MoFlo Sorter (Beckman Coulter). For donor-derived cell analysis in PB, rbc-free cells were stained with FITC-CD45.1, APC-CD45.2, and/or Alexa Fluor 700-CD45.2 (BD Biosciences). For analysis of multilineage blood cells, GR1-V450 (eBioscience), B220-APC-Cy7 (eBioscience), and THY1.2-APC (eBioscience) antibodies were used. To assess proliferation, LSK markers were stained with KI67-FITC or KI67-PerCPcy5.5 antibody (eBioscience). All FACS data were analyzed by FlowJo software (Tree Star Inc.). For counting BM stromal cells, PE-TER119 and APC-CD45 antibodies (eBioscience) were used. PB analysis. Complete blood counts were analyzed by a Hemavet 950FS (Drew Scientific).
BMT. For competitive transplantation assays, 1,000 sorted LSK cells from MxCre-Keap1 flox/flox or Keap1 flox/flox mice were injected retro-orbitally into lethally irradiated congenic CD45.1 + WT recipient mice with 250,000 CD45.1 + competitive cells. For the short-term repopulation assay, 500,000 whole BM cells or 1,000 donor LSK cells were injected into lethally irradiated (10 Gy) recipient mice.
Isolation of BM stromal cells and ex vivo culture. BM cells from mice (Nrf2 +/+ , Nrf2 -/-, or floxed control CMV-Keap1Cre) were collected by flushing the femurs and tibias with IMDM supplemented with 5% FCS. BM cells that were rbc depleted were plated onto a 12-well plate at a density of 5 × 10 6 cells per well. Culture medium was changed daily to remove the nonadherent cells, and the adherent BM stromal cells were treated with different concentrations of TMC or vehicle (DMSO) after 48 hours of culture (70) . Sorted LSK cells (500-1,000 cells) were cocultured with BM stromal cells pretreated with pharmacological NRF2 activator or 4-hydroxy-tamoxifen. Culture medium containing IMDM plus 10% FBS, 1% penicillin-streptomycin, thrombopoietin, SCF, and FLT3 ligand (TSF) was prepared as previously described (43) .
CFC assays. CFC assays were performed using MethoCult M3434 (STEM-CELL Technologies) as previously described (24) .
Quantita tive real-time RT-PCR. Total RNA was extracted from cells or tissues using the RNeasy Mini Kit according to the manufacturer's protocol (QIAGEN). Quantitative real-time RT-PCR analyses were conducted using
Methods
Mice. C57BL/6, CD-1 and SJL/C57BL/6 CD45.1 mice were obtained from the National Cancer Institute (NCI) and The Jackson Laboratory, respectively. Keap1 flox/flox mice on a C57BL/6 background were generated as previously described (65, 66) . MxCre-Keap1 flox/flox mice were generated by crossing Keap1 flox/flox mice with Mx1-Cre + mice (The Jackson Laboratory). To induce Cre-mediated deletion of Keap1 in the hematopoietic lineage, MxCre-Keap1 flox/flox or Keap1 flox/flox mice were administered with polyriboinosinic acid-polyribocytidylic acid [poly(I:C)] (Sigma-Aldrich) for 7 days (25 mg/kg/day) (67) . Tamoxifen-inducible CMVCre-Keap1 flox/flox mice were generated by crossing Keap1 flox/flox mice with CAG-CreERT2 + mice (The Jackson Laboratory). To induce Cre-mediated deletion of Keap1, tamoxifen-inducible CMVCre-Keap1 flox/flox or Keap1 flox/flox mice were treated with tamoxifen for 5 days (1 mg/mouse/day; i.p. injection). Deletion of Keap1 exons 2-3 were confirmed by PCR analysis using primers: forward 5′-GAGTCCACAGTGT-GTGGCC-3′, reverse 5′-GAGTCACCGTAAGCCTGGTC-3′. Generation of NRF2-deficient C57BL/6 mice was described previously (68) .
Pharmacological NRF2 activators. TMC was synthesized as previously described (28) . CDDO-Me was provided by Michael B. Sporn (Dartmouth Medical School).
TBI and treatment. Mice were exposed to whole-body IR using a Gammacell 40 Exactor cesium-137 irradiator (Atomic Energy Commission of Canada, Ltd.), with an average dose rate of 0.53 Gy/min −1 at the Johns Hopkins School of Medicine Radiation Oncology Department. For assessing survival rates, mice were monitored for up to 30 days after TBI. For evaluation of the radiomitigating efficacy of TMC, irradiated mice were administered orally with TMC (10 mg/mice/day) or an equal volume of vehicle 6 times, once every 48 hours, beginning 1, 6, or 24 hours after TBI. For safety studies, normal mice were administered orally with TMC or vehicle daily for 2 weeks. TMC was dissolved in a formulation consisting of 5% DMSO and 95% polyethylene glycol (PEG) 200. To test the radiomitigating effect of CDDO-Me, mice were treated every 48 hours with CDDO-Me or vehicle by oral gavage 1, 6, and 24 hours after TBI. CDDO-Me was dissolved in 10% DMSO, 10% cremophor-EL, and 80% PBS. The dose of CDDO-Me was 10 μmol/kg body weight.
Isolation of BM cells and flow cytometry. BM cell isolation, LSK cell sorting, and flow cytometric analysis of cell surface markers were performed as previously described (43, 69) . Briefly, BM cells were flushed from the long bones (tibias and femurs) of mice with Iscove's modified Dulbecco's
Figure 8
TMC enhanced expansion of HSPCs ex vivo by upregulating JAG1 in BM stromal cells in an NRF2-dependent manner. (A) Expression of Nqo1 and Gclm in BM stromal cells isolated from Nrf2 +/+ or Nrf2 -/unirradiated mice 12 hours after exposure to TMC (1 μM) or DMSO. Data represent the mean ± SD. ***P < 0.001 and *P < 0.05 compared with vehicle-treated mice. (B) Jag1 mRNA expression in Nrf2 +/+ and Nrf2 -/stromal cells isolated from BM 12 hours after exposure to increasing doses of TMC or DMSO in vitro. ***P < 0.001. (C) LSK cells isolated from irradiated mice were cocultured with TMC-(1 μM) or vehicle-exposed Nrf2 +/+ or Nrf2 -/-BM stromal cells, and the total number of LSK cells was enumerated on day 7. ***P < 0.001. (D) LSK cells were cocultured with TMC-(1 μM) or vehicle-exposed BM stromal cells in the presence or absence of anti-JAG1 antibody, and the total number of LSK cells was enumerated on day 7. LSK and BM stromal cells were isolated from irradiated mice. For neutralization of JAG1, TMC-or vehicle-treated BM stromal cells were incubated with anti-JAG1 antibody prior to incubation with CD34 -LSK cells. *P < 0.05; **P < 0.01.
